Background
==========

Kidney transplantation is currently considered the definitive treatment for patients with end-stage kidney disease with well-documented survival benefits over dialysis \[[@b1-medscimonit-23-3770]\]. With a limited donor pool and an expanding transplant waiting list, consideration of organs from infected donated after donor cardiac death (DCD) is necessary \[[@b2-medscimonit-23-3770]--[@b5-medscimonit-23-3770]\]. However, the utilization of organs from donors not meeting standard donor criteria has been associated with infections transmitted by the transplanted organs \[[@b6-medscimonit-23-3770],[@b7-medscimonit-23-3770]\]. The overall safety and favorable outcomes related to donor-transmitted bacterial infections among solid organ transplantation have been reported \[[@b8-medscimonit-23-3770],[@b9-medscimonit-23-3770]\].

Although the transmission of infections from a donor to a recipient is a rare complication of kidney transplantation, it is typically associated with significant mortality (more than 17%) \[[@b10-medscimonit-23-3770]--[@b16-medscimonit-23-3770]\].

Currently, the data on DCD donor-derived bacterial or fungal infections are lacking in China. We aimed to investigate blood and urine cultures of DCD donors and report the cases of confirmed (proven/probable) transmission of bacterial or fungal infection from donors to kidney recipients. Our present study represents the largest sample size of kidney recipients experiencing confirmed donor-derived fungal or bacterial infections reported by a single transplant center thus far.

Material and Methods
====================

Study population
----------------

A retrospective study, at a single center, was conducted with the purpose of recording all cases of donor-derived bacterial and fungal infections between January 1, 2010 and April 1, 2016. We did not monitor cytomegalovirus and Epstein-Barr virus in every donor, however, we monitored hepatitis B virus (HBV) and hepatitis C virus in every donor and recipient, and found 15 donors underwent HBV infection and no donors developed hepatitis C virus infection when the grafts were procured. Three kidney recipients who had HBV infection before transplantation underwent relapse of HBV infection under the treatment of anti-HBV treatment. All these three recipients obtained kidney grafts from donors with HBV infection. We could not confirm these three recipients with donor-derived HBV infection. Thus, we did not include donor-derived viral infection in this cohort.

The study population consisted of 154 kidney recipients of grafts from 78 DCD donors, who were admitted into intensive care unit (ICU) of the Department of Transplant Surgery, the Third Xiangya Hospital of Central South University, Changsha, China, before organ procurement and transplantation. Multi-organ transplant recipients were excluded from the study. Data collections included donor age, gender, length of ICU stay, number of donors with/without available results of blood or urinary cultures, bacteria and fungi isolated from donors, site of infection, antibiotic administration, and cause of death. Variables associated with the recipients with donor-derived infection were collected from their medical records: age, gender, underlying kidney diseases, site of infection, time of infection onset, organisms, antimicrobial use, immunosuppressive therapy, evaluated glomerular filtration rate (eGFR) at one week after transplantation, serum creatinine level before hospital discharge or death, and crude mortality/graft loss. Maintenance immunosuppression was tacrolimus/cyclosporin-based and was complemented with mycophenolate mofetil and prednisone tapered to 5--10 mg/day. The clinical course of recipients was followed for at least six months after the onset of infection. The Ethics Committee of the Third Xiangya Hospital approved this study (tHIRB number: 2016-S249).

Definition
----------

Transmission of the organisms was confirmed (proven/probable) when bacterial or fungal isolates from donor and at least one of the kidney recipient or two recipients from the same donor showed a similar resistance profile and when the absence of pre-transplant infectious disease in the recipients was documented \[[@b17-medscimonit-23-3770]\]. Appropriate antimicrobial use in donors was considered when the infected donor receives targeted antimicrobial treatment for at least 24--48 hours, optimally with some degree of clinical response (improved white blood cell count, improved hemodynamics, defervescence) \[[@b18-medscimonit-23-3770]\]. Appropriate antimicrobial use in recipients was considered if organisms isolated were *in vitro* susceptible to empirical antibiotics, which were administered within 48 hours of sampling for culture \[[@b19-medscimonit-23-3770]\]. Death was regarded as infection-related when it was associated with clinical signs of active infection without evidence of any other cause \[[@b20-medscimonit-23-3770]\].

Statistical analysis
--------------------

Continuous variables were expressed as mean ± standard deviations or median (interquartile range \[IQR\]). Mann-Whitney U-test or *t-*test was used for continuous variables and chi-squared test or Fisher exact test was used for comparison of categorical and binary variables, as appropriate. Univariate analysis was applied to examine the association between variables from donors or recipients and donor-derived infection. Statistical analyses were performed using the statistical package SPSS version 22.0 for Windows (SPSS Inc., Chicago, IL, USA). A *p* value \<0.05 was considered statistically significant, and all tests of significance were two tailed.

Results
=======

There were 154 kidney recipients of graft from 78 DCD donors during the study period. Four out of 26 (15.4%) donors with urinary and/or bloodstream infections developed confirmed transmission of bacterial or fungal infections, affecting seven kidney recipients and resulting in three crude mortality including at least one infection-related death.

Donor characteristics and the risk factors of donor for donor-derived infection
-------------------------------------------------------------------------------

The characteristics of the donors are shown in [Table 1](#t1-medscimonit-23-3770){ref-type="table"}. The median age was 33.5 years with a gender distribution of 61 males/17 females (sex ratio 3.6). The most common origin of death was head injury, followed by central nervous system benign tumor. Thirteen of 78 donors did not available results for both bloodstream and urine cultures. Screening results for blood and urine cultures were available for 61 (77.2%) and 43 (54.4%) DCD donors, respectively. Twenty-two episodes of bloodstream infections and 17 episodes of urinary infections developed in 18 and 14 donors, respectively. The number of donors with a positive culture of blood and urine alone, and in combination, was 12, eight, and six, respectively. Appropriate antimicrobial use in donors with positive blood and urine culture results were 13/18 and 9/14, respectively. Results of urinary and blood cultures of the donors are shown in [Table 2](#t2-medscimonit-23-3770){ref-type="table"}. The majority (63.6%; 14/22) of pathogens isolated from donor's blood were coagulase-negative *staphylococci* and *Staphylococcus aureus*.

The comparison of the characteristics of four DCD donors resulting in infectious transmissions with 74 DCD donors without leading to transmissions is shown in [Table 3](#t3-medscimonit-23-3770){ref-type="table"}. We did not find a difference in age, gender, origin of death, ICU stay, site of infection, type of organisms, resistant to antimicrobial drugs, and creatinine level before graft procured between donors with and without leading to infectious transmissions. However, the inappropriate use of antibiotics in donors was a risk factor for donor-derived infection (*p*=0.048).

The characteristics of recipients with donor-derived infection
--------------------------------------------------------------

[Table 4](#t4-medscimonit-23-3770){ref-type="table"} showed the characteristics of the donors and the corresponding kidney recipients to make a clearer relationship between donors and recipients. Seven kidney recipients developed confirmed donor-derived bacterial or fungal infections. Recipients 1 and 2 were classified as a proven donor-derived infection and recipients 3 through 7 were classified as a probable donor-derived infection.

Several cultures (blood, urine, and organ-space surgical site infections) were routinely taken following kidney transplantation. Transmitted pathogens included *Klebsiella pneumoniae* in three cases, and *Staphylococcus aureus* and *Candida albicans* each in two cases. No recipient had a presumed or confirmed invasive bacterial or fungal infection pre-transplantation. Two *Candida albicans* rods isolated from recipients with donor-derived infection were susceptible to the common used anti-fungal drugs whereas three *Klebsiella pneumoniae* specimens were multidrug resistant (MDR) and two *Staphylococcus aureus* specimens were methicillin-resistant.

Three out of seven recipients who had donor-derived infections received appropriate anti-microbial therapy. Two of three cases of *Klebsiella pneumoniae* transmission received appropriate anti-microbial therapy. One case who did not receive appropriate therapy died with graft loss. Two of four donors who received appropriate therapy resulted in infectious transmission in three kidney recipients, one with bloodstream infection owing to MDR *Klebsiella pneumoniae* and two with organ-space surgical site infections caused by methicillin-resistant *Staphylococcus aureus* ([Table 4](#t4-medscimonit-23-3770){ref-type="table"}).

Underlying kidney diseases of these seven recipients consisted of three chronic glomerulonephritis cases, two diabetic nephropathy cases, and one polycystic kidney disease case. All these patients received similar postoperative intensive care with a routine triple immunosuppressive regimen including corticosteroids (n=7), mycophenolate mofetil (n=7), and FK506 (tacrolimus) (n=6) or cyclosporine (n=1). In addition, six patients received antithymocyte or antilymphocyte globulin during the induction phase of immunosuppression after kidney transplantation. Time to onset of donor-derived infection was a median of eight days (IQR 2--10). All donor-derived infection occurred within one month post-transplantation (from 1--20 days). Organ-space surgical site infections were the predominant site of infection (57.1%). The characteristics, underlying kidney disease, and urinary and blood culture results concerning the seven patients with donor-derived infection are shown in [Table 5](#t5-medscimonit-23-3770){ref-type="table"}.

Outcomes of kidney recipients with donor-derived infection
----------------------------------------------------------

Among the kidney recipients with donor-derived infection during the at least six months of follow-up, there was a strikingly high crude mortality rate of 42.9% (3/7); one kidney recipient died due to multi-organ failure two months after combined transmission of candida urinary tract infection and candidemia and two patients died owing to rupture of the renal artery. Ultrasonography result of the patient with rupture of the renal artery was not consistent with mycotic aneurysm. The culture of the organ-space surgical site showed only an isolated growth of *Klebsiella Pneumonia* in one patient with renal artery rupture. Thus *Klebsiella Pneumonia* was the most probable causative microorganism leading to this episode of renal artery rupture. This patient died of sudden bleeding from the renal artery and we could not confirm that the renal artery rupture was secondary to *Klebsiella Pneumonia*. Two recipients did not receive appropriate antimicrobial therapy after infection among these three patients who died. Of three recipients with crude hospital mortality, all developed allograft dysfunction, and the serum creatinine level of two of them was more than 600 μmol/L at the point of death (serum creatinine were 207, 629, and 621 μmol/L, respectively).

The comparison of the characteristics of kidney recipients with and without donor-derived infection
---------------------------------------------------------------------------------------------------

[Table 6](#t6-medscimonit-23-3770){ref-type="table"} shows the characteristics of kidney recipients with donor-derived infection compared with those without donor-derived infection. The use of FK506 was less frequent in patients with donor-derived infection (71.4%) compared with those without donor-derived infection (96.6%). Recipients with donor-derived infection were associated with higher mortality and graft loss (42.9% and 28.6%, respectively), when compared with those without donor-derived infection (4.8% each) (*p*\<0.001 each). Seven out of 147 kidney recipients without donor-derived infection died. Among them, six died of pneumonia or bloodstream infections caused by *Pseudomonas aeruginosa*, *Acinetobacter baumannii*, *Streptococcus anginosus*, or *Staphylococcus haemolyticus*. No deaths in the rest of the cohort were secondary to infection from similar organisms isolated from recipients with donor-derived infection.

Discussion
==========

Although there are numerous reports of fatal donor-derived infection affecting around 3% of solid organ transplants, the use of grafts from infection risk donors represents a strategy to expand the limited donor pool \[[@b21-medscimonit-23-3770]\]. Since prolonged duration of dialysis is a crucial risk factor for patient mortality, it is logical to infer that increasing utilization of infection risk kidneys can shorten waiting times and improve long-term patient outcomes \[[@b22-medscimonit-23-3770],[@b23-medscimonit-23-3770]\].

More recent data suggest that bacteremic donors may be considered, provided bacteremia in the donor was ideally treated and resolved prior to transplantation or the donor received appropriate antimicrobial treatment for at least 48 hours and antibiotic therapy was continued in the organ recipient \[[@b6-medscimonit-23-3770],[@b8-medscimonit-23-3770],[@b9-medscimonit-23-3770],[@b24-medscimonit-23-3770],[@b25-medscimonit-23-3770]\]. Our present study found 29.5% (18/61) of donors (who had available results of blood cultures) developed bloodstream infections and only two kidney recipients were associated with donor-derived bloodstream infection, which is in line with literature reports suggesting that about 5% of all deceased donors have unrecognized bacteremia at the time of donation but that few instances are associated with recipient disease \[[@b8-medscimonit-23-3770],[@b25-medscimonit-23-3770],[@b26-medscimonit-23-3770]\]. However, in a review of 610 liver transplants, 69 donors had bloodstream infections prior to procurement and in four (5.8%), there was transmission to the recipient despite directed antimicrobial prophylaxis \[[@b6-medscimonit-23-3770]\].

Our kidney recipients had a higher occurrence rate of donor-derived infection (4.5%) than the previous reports. This apparent discrepancy might be due to inadequate sample size. Furthermore, in some centers, cases that are associated with less severe disease (e.g., transient bacteremia that responds quickly to therapy) are likely to be under-recognized and, therefore under-reporting may be significant \[[@b27-medscimonit-23-3770]\]. Furthermore, a thorough review of cultures for all kidney recipients of organs from DCD donors has now been implemented at our institute. The high occurrence rate of infectious transmission is not surprising since every kidney recipient in our center underwent routine surveillance cultures of urine, blood, and drainage fluid of organ-space surgical site post-transplant even if the recipients lacked symptoms of active infections. Meanwhile, our donors' infection rate was higher than other centers, which contributed to a higher occurrence rate of donor derived infectious transmission \[[@b4-medscimonit-23-3770]\]. The 2013 report \[[@b28-medscimonit-23-3770]\] from the Organ Procurement and Transplantation Network (OPTN) Ad Hoc Disease Transmission Advisory Committee revealed that 15 out of 117 (12.8%) donors with infections developed proven/probable transmission of bacterial (except for tuberculosis) and fungal infections, which agreed with our present occurrence rate of 4/26 (15.4%).

We found all donor-derived bacterial and fungal infections occurred within one month post-transplantation, which was accordant with a review of the Disease Transmission Advisory Committee experience from 2008--2012 which claimed the majority (86%) of transmission of bacterial and fungal infections developed within one month post-transplant \[[@b29-medscimonit-23-3770]\].

Several studies reported that coagulase-negative *staphylococci* (such as *Staphylococcus epidermidis*) and *Staphylococcus aureus*, represent more commonly isolated microorganisms from donor blood cultures \[[@b9-medscimonit-23-3770],[@b25-medscimonit-23-3770],[@b26-medscimonit-23-3770]\]. We also found the majority (63.6%; 14 of 22 pathogens isolated from donor blood cultures) were coagulase-negative *staphylococci* and *Staphylococcus aureus.* Our present study found two kidney recipients with donor-derived infection due to *Staphylococcus aureus*. To date, there have been several reports of suspected donor-transmitted *Staphylococcus aureus* infections in SOT recipients \[[@b7-medscimonit-23-3770],[@b30-medscimonit-23-3770]--[@b32-medscimonit-23-3770]\]. However, Ison et al. suggested there was a low risk of transmission of coagulase-negative *staphylococci* from a donor to a recipient \[[@b8-medscimonit-23-3770]\]. Likewise, none of 11 donors with coagulase-negative *staphylococci* in our cohort developed proven/probable transmission.

We found inappropriate use of antibiotics in donor was a risk factor for donor-derived infection. We also found the use of FK506 was more frequent in recipients without donor-derived infection than those with donor-derived infection. It is not surprising that inappropriate use of antibiotics in donors was associated with more donor-derived infections. However, it is not clear why the use of FK506 was more frequent in recipients without donor-derived infection than those with donor-derived infection. We did not investigate the immunosuppression level in this study which may at least partly explain this finding.

*Candida* spp. transmitted from donors to the recipients was reported to be more prone to cause fatal early post-transplant complications, such as bloodstream infection or mycotic aneurysm \[[@b33-medscimonit-23-3770]\]. A growing body of evidence reveals that donor-derived fungal infections are a significant complication in kidney recipients that can be related to grave even fatal outcomes with mortality rate of up to 100% \[[@b11-medscimonit-23-3770]--[@b14-medscimonit-23-3770],[@b16-medscimonit-23-3770],[@b34-medscimonit-23-3770]\]. In our present study, 1/2 (50%) kidney recipient with fungal infection died due to combined transmission of candida urinary tract infection and candidemia.

Outcomes of recipients with donor-derived infection caused by bacteria, in particular resistant bacteria, were also quite poor \[[@b10-medscimonit-23-3770],[@b15-medscimonit-23-3770],[@b35-medscimonit-23-3770]\]. Lewis et al. summarized all published cases and found the mortality rate for those who developed a MDR bacterial donor-derived infection was 33% \[[@b36-medscimonit-23-3770]\]. Two (40%) recipients with MDR *Klebsiella pneumoniae* infection died related to rupture of the renal artery in our present study.

Our kidney recipients with donor-derived infection showed a high morbidity (4.5%) and crude mortality (42.9%). The majority of recipients with donor-derived infection who died did not receive appropriate antimicrobial therapy after infection. Recipients with donor-derived infection were associated with higher mortality and graft loss (42.9% and 28.6%, respectively), when compared with those without donor-derived infection (4.8% each) with a follow-up time of at least six months. Our findings agreed with the data reported to the United States OPTN from 2005 to 2011 which showed the donor-derived infection-attributable recipient mortality rate of 29.2% (19/65) \[[@b8-medscimonit-23-3770]\]. We need further data to assess the effect of donor-derived bacterial or fungal infections and inappropriate antimicrobial use on allograft function and recipient survival over a long-term follow up.

Currently, transplant centers in China are not required to report infectious transmission so that any data available relies on voluntary reporting by individual centers. Our present study, however, revealed that because both the morbidity and mortality of donor-derived infection are high in China, this advocates for a better understanding of potential risks for disease transmission and underpins the necessity for a standardized critical incident reporting system in the Chinese transplant system to improve short- and long-term allograft and recipient's survival.

To the best of our knowledge, our present study represents the largest sample size of kidney recipients with confirmed donor-derived fungal or bacterial infections reported by a single transplant center thus far. The principal limitation of our study was a single-center study and its retrospective nature which did not allow us to demonstrate by genetic or molecular analysis that bacteria or fungi affecting the DCD donors were the source of infection in the kidney recipients. Since we used drug-sensitive test screening for donor-derived infection rather than a gene level it is possible that our testing algorithm over-estimated the transmission events.

We need to change the policy in our institute to prevent donor-derived infection. First, surveillance culture of urine and blood should be performed periodically in every donor, in particular at the time of organ procurement. Donors should be treated for 24--48 hours with antibiotics directed at the identified bacteria or fungi prior to procurement, optimally with evidence of clinical improvement. Second, the preservation fluid sample should be cultured. Finally, the recipients should be treated for 7--14 days post-transplant with antibiotics directed at the cultured bacteria isolated from donors or the preservation fluid samples. Antifungal therapy directed at the identified fungi should continue for more than two weeks unless there is no clinical or microbiologic evidence of infection.

Conclusions
===========

DCD donors had high bacterial or fungal infection with Gram-positive bacteria being predominant isolates whereas kidney recipients had a Gram-negative predominant donor-derived infection. Our findings strongly supported organ donation as the common source of bacterial or fungal infection in the kidney recipients. We found inappropriate use of antibiotics in donors was a risk factor for donor-derived infection. Furthermore, our kidney recipients with donor-derived infection showed a higher crude mortality and graft loss than those without donor-derived infection. Recipients who succumbed to donor-derived infection had higher inappropriate antibiotic use after infection, which emphasized the need of vigilant post-transplant clinical surveillance for timely and prompt targeted anti-infective prophylaxis or preemptive therapy in the event of donor-derived infection.
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###### 

The characteristic of 78 DCD donors.

  Characteristics                                                                       Value
  ------------------------------------------------------------------------------------- ---------------
  Median age (range, years)                                                             33.5 (2--62)
  Sex, number of male/number of female                                                  61/17
  Origin of death                                                                       
   HI                                                                                   35
   CNS benign tumor                                                                     20
   CVA                                                                                  18
   Anoxia                                                                               4
   Meningitis                                                                           1
  ICU stay, median days (IQR)                                                           5 (2.8--11.0)
  Donors with positive culture                                                          
   Positive blood culture                                                               12
   Positive urine culture                                                               8
   Positive blood + urine culture                                                       6
  Blood culture, number of donors with/without available results                        61/78
  Appropriate antimicrobial use donors/all donors with positive blood culture results   13/18
  Urine culture, number of donors with/without available results                        43/78
  Appropriate antimicrobial use donors/all donors with positive urine culture results   9/14
  No available results for both bloodstream and urine cultures                          13/78

DCD -- donated after cardiac death; HI -- head injury; CNS -- central nervous system; CVA -- cerebrovascular accident; ICU -- intensive care unit; IQR -- interquartile range.

###### 

Classification and percentage of organisms from donors.

  Organisms                              Strain (n=39)   Percentage
  -------------------------------------- --------------- ------------
  **Blood culture**                      22              56.4
   Gram-positive bacteria                15              38.5
    *Staphylococcus aureus*              3               7.7
    *Enterococcus faecalis*              1               2.6
    Coagulase *Negative Staphylococci*   11              28.2
     *Staphylococcus epidermidis*        4               10.3
     *Staphylococcus hemolyticus*        2               5.1
     *Staphylococcus capitis*            2               5.1
     *Staphylococcus cohnii*             1               2.6
     *Staphylococcus hominis*            1               2.6
     *Staphylococcus simulans*           1               2.6
   Gram-negative bacteria                4               10.3
    *Klebsiella pneumoniae*              2               5.1
    *Escherichia coli*                   1               2.6
    *Acinetobacter baumannii*            1               2.6
   Fungi                                 3               7.7
    *Candida albicans*                   2               5.1
    *Candida parapsilosis*               1               2.6
  **Urine culture**                      17              43.6
   Gram-positive bacteria                4               10.3
    *Enterococcus faecalis*              2               5.1
    *Staphylococcus aureus*              1               2.6
    *Staphylococcus chromogenes*         1               2.6
   Gram-negative bacteria                5               12.8
    *Acinetobacter baumannii*            2               5.1
    *Pseudomonas aeruginosa*             2               5.1
    *Klebsiella pneumoniae*              1               2.6
   Fungi                                 8               20.5
    *Candida albicans*                   5               12.8
    *Candida parapsilosis*               2               5.1
    *Candida krusei*                     1               2.6

###### 

The comparison of the characteristic of 4 DCD donors resulting in infectious transmissions with 74 DCD donors without leading to transmissions.

  Characteristics                                                                                 Donors resulting in infectious transmissions (n=4)   Donors without leading to transmissions (n=74)   P
  ----------------------------------------------------------------------------------------------- ---------------------------------------------------- ------------------------------------------------ -------
  Age, mean years ±SD                                                                             36.25±20.27                                          32.15±15.25                                      0.602
  Male sex, n (%)                                                                                 4 (100%)                                             57 (77%)                                         0.278
  Origin of death, n (%)                                                                                                                                                                                0.237
   HI                                                                                             1 (25%)                                              34 (45.9%)                                       
   CNS benign tumor                                                                               1 (25%)                                              19 (25.7%)                                       
   CVA                                                                                            1 (25%)                                              17 (23%)                                         
   The others                                                                                     1 (25%)                                              4 (5.4%)                                         
  ICU stay, median days (IQR)                                                                     11 (7.25--16.25)                                     4 (2--10.25)                                     0.212
  Site of infection[a](#tfn3-medscimonit-23-3770){ref-type="table-fn"}, n (%)                                                                                                                           0.916
   Positive urine and/or blood culture 6                                                          1 (25%)                                              25 (33.8%)                                       
   Negative culture for urine and/or blood                                                        3 (75%)                                              36 (48.6%)                                       
  Type of organisms[b](#tfn3-medscimonit-23-3770){ref-type="table-fn"}, n (%)                                                                                                                           0.666
   Bacteria+ Fungi                                                                                1 (25%)                                              35 (47.3%)                                       
   Negative culture                                                                               3 (75%)                                              36 (48.6%)                                       
  Resistant to multiple antimicrobics[c](#tfn3-medscimonit-23-3770){ref-type="table-fn"}, n (%)   0 (0%)                                               16 (21.6%)                                       0.576
  Inappropriate use of antibiotics[d](#tfn3-medscimonit-23-3770){ref-type="table-fn"}, n (%)      2 (50%)                                              5 (6.8%)                                         0.048
  Creatinine level before graft procured, median μmol/L (IQR)                                     42 (23.25--57)                                       51 (35--77.25)                                   0.326

DCD -- donated after cardiac death; HI -- head injury; CNS -- central nervous system; CVA -- cerebrovascular accident; ICU -- intensive care unit; IQR, interquartile range.

Only 65 kidney recipients who had available blood and/or urine culture were analyzed.

###### 

The characteristics of the donors and the corresponding kidney recipients.

  Donor   Diagnosis                       Culture result                  Inappropriate antimicrobics           Recipient                Culture result            Inappropriate antimircotics   Outcome
  ------- ------------------------------- ------------------------------- ------------------------------------- ------------------------ ------------------------- ----------------------------- --------------------------
  D1      Anoxia                          *C. albicans* (urine + blood)   Yes                                   R1                       *C. albicans* (urine)     Yes                           Patient/graft survival
  R2      *C. albicans* (urine + blood)   Yes                             Patient died/ normal graft function                                                                                    
  D2      HI                              Negative (urine + blood)        Yes                                   R3 a                     *K. pneumoniae* (OSSS)    No                            Patient died/ graft loss
  R4 a    *K. pneumoniae* (OSSS)          No                              Patient/graft survival                                                                                                 
  D3      HI                              Negative (urine + blood)        No                                    R5 b                     *K. pneumoniae* (blood)   Yes                           Patient died/ graft loss
  D 4     CNS tumor                       Negative (urine + blood)        No                                    R6                       *S. aureus* (OSSS)        Yes                           Patient/graft survival
          R7                              *S. aureus* (OSSS)              No                                    Patient/graft survival                                                           

HI -- head injury; OSSS -- organ-space surgical site; CNS -- central nervous system.

The liver recipient of graft from the same donor as these two kidney recipients underwent bloodstream infection and peritonitis owing to *Klebsiella pneumoniae* immediately after transplantation;

The liver recipient of graft from the same donor as this kidney recipient also underwent bloodstream infection owing to *Klebsiella pneumoniae* immediately after transplantation.

###### 

Characteristics, underlying kidney diseases, results of cultures and outcome of the 7 kidney recipients with DCD donor-derived infections.

  Characteristics                                                                       Value
  ------------------------------------------------------------------------------------- ----------------
  Median age (range, years)                                                             45 (20--62)
  Sex, number of male/number of female                                                  5/2
  Underlying kidney diseases                                                            
   Chronic glomerulonephritis                                                           4 (57.1)
   Diabetic nephropathy                                                                 2 (28.6)
   Polycystic kidney disease                                                            1 (14.3)
  Patient immunosuppressant treatment, no. of cases (%)                                 
   ATG or ALG + FK506 + MMF + Pred                                                      4 (57.1)
   FK506 + MMF + Pred                                                                   1 (14.3)
   ALG + CSA + MMF + Pred                                                               1 (14.3)
   CSA + MMF + Pred                                                                     1 (14.3)
  Site of infection, no. of cases (%)                                                   
   Organ-space surgical site infections                                                 4 (57.1)
   Blood                                                                                1 (14.3)
   Urinary tract                                                                        1 (14.3)
   Multiple culture-positive sites[a](#tfn8-medscimonit-23-3770){ref-type="table-fn"}   1 (14.3)
  Organisms                                                                             
   *Klebsiella pneumoniae*                                                              3 (42.9)
   *Candida albicans*                                                                   2 (28.6)
   *Staphylococcus aureus*                                                              2 (28.6)
  Time of infection onset, median days (interquartile range)                            8 (2--10)
  Serum creatinine at discharge or death, median (μmol) (interquartile range)           207 (113--621)
  Appropriate antimicrobial use, no. of cases (%)                                       3 (42.9)
  Crude hospital mortality, no. of cases (%)                                            3 (42.9)

DCD -- donated after cardiac death; ATG -- antithymocyte globulin; ALG -- antilymphocyte globulin; FK506 -- tacrolimus; MMF -- mycophenolat mofetil; Pred -- prednison; CSA -- cyclosporine A.

One bacteremia+urinary tract infection due to *Candida albicans.*

###### 

Characteristics of 154 kidney recipients with or without donor-derived infection.

  Characteristics                                                                          Recipients with donor-derived infection (n=7)   Recipients without donor-derived infection (n=147)   *P*
  ---------------------------------------------------------------------------------------- ----------------------------------------------- ---------------------------------------------------- ---------
  Age, mean years ±SD                                                                      44.86±15.18                                     39.41±10.93                                          0.205
  Male sex, n (%)                                                                          5 (71.4%)                                       105 (71.4%)                                          1.000
  ALG or ATG induction therapy, n (%)                                                      5 (71.4%)                                       99 (67.3%)                                           0.308
  The use of FK506, n (%)                                                                  5 (71.4%)                                       142 (96.6%)                                          0.033
  eGFR level 1 week after transplantation, median ml/min/1.73 m^2^ (interquartile range)   9.27 (5.96--50)                                 45.58 (18.05--71.51)                                 0.14
  Recipient death, n (%)                                                                   3 (42.9%)                                       7 (4.8%)                                             \<0.001
  Graft loss, n (%)                                                                        2 (28.6%)                                       7 (4.8%)                                             \<0.001

SD -- standard deviation; ALG -- antilymphocyte; ATG -- antithymocyte; FK506 -- tacrolimus; eGFR -- evaluated glomerular filtration rate.
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